Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 3 of 3 entries
Sorted by: Best Match Show Resources per page
Safety profile of the yellow fever vaccine Stamaril®: a 17-year review.

Expert review of vaccines

Cottin P, Niedrig M, Domingo C.
PMID: 24066727
Expert Rev Vaccines. 2013 Nov;12(11):1351-68. doi: 10.1586/14760584.2013.836320. Epub 2013 Sep 25.

Since the creation by the manufacturer in 1993, of an electronic pharmacovigilance database for all spontaneous, voluntary reports of adverse events (AEs) after vaccination, 276 million doses of Stamaril® have been distributed worldwide. We review this database for the...

Cite
Cottin P, Niedrig M, Domingo C. Safety profile of the yellow fever vaccine Stamaril®: a 17-year review. Expert Rev Vaccines. 2013;12(11):1351-68doi: 10.1586/14760584.2013.836320.
Cottin, P., Niedrig, M., & Domingo, C. (2013). Safety profile of the yellow fever vaccine Stamaril®: a 17-year review. Expert review of vaccines, 12(11), 1351-68. https://doi.org/10.1586/14760584.2013.836320
Cottin, Pascale, et al. "Safety profile of the yellow fever vaccine Stamaril®: a 17-year review." Expert review of vaccines vol. 12,11 (2013): 1351-68. doi: https://doi.org/10.1586/14760584.2013.836320
Cottin P, Niedrig M, Domingo C. Safety profile of the yellow fever vaccine Stamaril®: a 17-year review. Expert Rev Vaccines. 2013 Nov;12(11):1351-68. doi: 10.1586/14760584.2013.836320. Epub 2013 Sep 25. PMID: 24066727.
Copy Download .nbib Format: NLM
Hepatitis B infection reported with cancer chemotherapy: analyzing the US FDA Adverse Event Reporting System.

Cancer medicine

Sanagawa A, Hotta Y, Kataoka T, Maeda Y, Kondo M, Kawade Y, Ogawa Y, Nishikawa R, Tohkin M, Kimura K.
PMID: 29663729
Cancer Med. 2018 Jun;7(6):2269-2279. doi: 10.1002/cam4.1429. Epub 2018 Apr 16.

We conducted data mining using the US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) database on spontaneously reported adverse events to evaluate the association between anticancer drug therapy and hepatitis B infection. Reports of hepatitis B...

Cite
Sanagawa A, Hotta Y, Kataoka T, et al. Hepatitis B infection reported with cancer chemotherapy: analyzing the US FDA Adverse Event Reporting System. Cancer Med. 2018;7(6):2269-2279doi: 10.1002/cam4.1429.
Sanagawa, A., Hotta, Y., Kataoka, T., Maeda, Y., Kondo, M., Kawade, Y., Ogawa, Y., Nishikawa, R., Tohkin, M., & Kimura, K. (2018). Hepatitis B infection reported with cancer chemotherapy: analyzing the US FDA Adverse Event Reporting System. Cancer medicine, 7(6), 2269-2279. https://doi.org/10.1002/cam4.1429
Sanagawa, Akimasa, et al. "Hepatitis B infection reported with cancer chemotherapy: analyzing the US FDA Adverse Event Reporting System." Cancer medicine vol. 7,6 (2018): 2269-2279. doi: https://doi.org/10.1002/cam4.1429
Sanagawa A, Hotta Y, Kataoka T, Maeda Y, Kondo M, Kawade Y, Ogawa Y, Nishikawa R, Tohkin M, Kimura K. Hepatitis B infection reported with cancer chemotherapy: analyzing the US FDA Adverse Event Reporting System. Cancer Med. 2018 Jun;7(6):2269-2279. doi: 10.1002/cam4.1429. Epub 2018 Apr 16. PMID: 29663729; PMCID: PMC6010750.
Copy Download .nbib Format: NLM
Adverse drug reactions reporting culture in Pharmacovigilance Programme of India.

The Indian journal of medical research

Kalaiselvan V, Prasad T, Bisht A, Singh S, Singh GN.
PMID: 25488454
Indian J Med Res. 2014 Oct;140(4):563-4.

No abstract available.

Cite
Kalaiselvan V, Prasad T, Bisht A, et al. Adverse drug reactions reporting culture in Pharmacovigilance Programme of India. Indian J Med Res. 2014;140(4):563-4
Kalaiselvan, V., Prasad, T., Bisht, A., Singh, S., & Singh, G. N. (2014). Adverse drug reactions reporting culture in Pharmacovigilance Programme of India. The Indian journal of medical research, 140(4), 563-4.
Kalaiselvan, Vivekanandan, et al. "Adverse drug reactions reporting culture in Pharmacovigilance Programme of India." The Indian journal of medical research vol. 140,4 (2014): 563-4.
Kalaiselvan V, Prasad T, Bisht A, Singh S, Singh GN. Adverse drug reactions reporting culture in Pharmacovigilance Programme of India. Indian J Med Res. 2014 Oct;140(4):563-4. PMID: 25488454; PMCID: PMC4277146.
Copy Download .nbib Format: NLM
Showing 1 to 3 of 3 entries